Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JSKN 003

Next Previous
Drug Profile

JSKN 003

Alternative Names: JSKN-003

Latest Information Update: 04 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alphamab Oncology
  • Class Antineoplastics; Bispecific antibodies; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Breast cancer; HER2 positive breast cancer
  • Phase I Solid tumours

Most Recent Events

  • 31 May 2025 Shanghai JMT-BIO Technology plans a phase-II trial for Gastric cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, First-line therapy) in June 2025 (IV), (NCT06998771)
  • 26 Feb 2025 Shanghai JMT-Bio plans a phase III trial for HER2-positive breast cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) (IV) (NCT06846437)
  • 18 Feb 2025 Phase-III clinical trials in HER2-positive-breast-cancer (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in China (IV) (NCT06846437)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top